NHS England gets commercialNHS England is no longer the new kid on the block, taking up its role in 2013. In Share XNHS England gets commercialhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/nhs-england-commercial-framework-vpas/
Under the skin of innovationLEO’s Innovation Lab is working at arm’s length from the main company to encourage original thinking and develop Share XUnder the skin of innovationhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/leo-innovation-lab-john-zibert-digital/
Nine for 2019: Opportunities for pharmaIn the last Nine for 2019 article, we reflected on the major challenges that are shaping the pharmaceutical Share XNine for 2019: Opportunities for pharmahttps://pharmaphorum.com/views-and-analysis/nine-for-2019-opportunities-for-pharma/
Nine for 2019: Challenges impacting pharmaAs we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping Share XNine for 2019: Challenges impacting pharmahttps://pharmaphorum.com/r-d/views-analysis-r-d/nine-for-2019-challenges-impacting-pharma/
ASCO 2019 – phase I data generates hope for the futureSometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share XASCO 2019 – phase I data generates hope for the futurehttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseaseAfter moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on Share XBeyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseasehttps://pharmaphorum.com/r-d/views-analysis-r-d/beyond-glucose-in-type-2-diabetes-how-novo-nordisk-is-looking-to-address-chronic-kidney-disease/
ASCO 2019 day fiveExclusive live coverage from day five of the American Society of Clinical Oncology’s annual meeting in Chicago. • Share XASCO 2019 day fivehttps://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-five/
ASCO 2019 – Enfortumab comes out fighting in bladder cancerAt ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) Share XASCO 2019 – Enfortumab comes out fighting in bladder cancerhttps://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/
ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultsAt ASCO, a lot of attention is given to the results of the large, clinical practices changing phase Share XASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultshttps://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/
